A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

Getting the HPV vaccine in early adolescence may lower the risk of HPV-related cancers before exposure occurs. Learn about ...

Fewer than half of patients testing positive for HPV received recommended annual follow-up testing, a new cohort study found.

However, if a woman is found to be HPV positive with a high-risk strand (HPV 16 and/or 18), also referred to as a high-grade lesion, she will then be sent for further testing right away.

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...

Fewer than half of women who tested positive for HPV with negative cytological findings returned for a surveillance co-test within 1 year as recommended, yet more than half of those who received ...

Among female patients with positive human papillomavirus (HPV) test results and negative intraepithelial lesion or malignancy ...

During the first 16 months after an index positive HPV result, only 43.7% of patients received an initial surveillance test, of whom 18.2% had HPV-negative results and negative intraepithelial ...